Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05493709 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
A Phase 3 study of Puberty; Precocious, Central, sponsored by Foresee Pharmaceuticals Co..
- Active
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
- 20
- Study locations
NCT05493709 is a Phase 3 study of Puberty; Precocious, Central that is active but no longer recruiting, run by Foresee Pharmaceuticals Co.. The registered enrollment target is 93 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05493709, a Phase 3 study of Puberty; Precocious, Central, is active but no longer recruiting, sponsored by Foresee Pharmaceuticals Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
Conditions Studied
Interventions
- DRUG Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
Study Locations (20)
Guangdong
- Pearl River Hospital, Southern Medical University - Guangzhou
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University - Guangzhou
- The First Affiliated Hospital, Sun Yat-sen University - Guangzhou
- The Third Affiliated Hospital, Sun Yat-Sen University - Guangzhou
Florida
- Nemours Children's Health Center - Jacksonville
- Johns Hopkins - All Children's Hospital - St. Petersburg
Texas
- University of Texas Southwestern Medical Center - Dallas
- Cook Children's - Fort Worth
Hubei
- Tongji Hospital, Tongji Medical College of HUST - Wuhan
- Wuhan Children's Hospital, Tongji Medical College of HUST - Wuhan
Arizona
- Arizona University - Tucson
California
- Rady Children's Hospital- San Diego - San Diego
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2023-06-02 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05493709
The ClinicalTrials.gov registry entry for NCT05493709 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Foresee Pharmaceuticals Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Puberty; Precocious, Central appearing as the primary indexed condition, and to 1 intervention - of which Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide is the first listed.
NCT05493709 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Guangdong, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05493709 about?
NCT05493709 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty". The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
What is the current status of trial NCT05493709?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2023-06-02. Estimated completion is 2026-06.
What conditions does trial NCT05493709 study?
This clinical trial studies the following conditions: Puberty; Precocious, Central.
What interventions are being tested in trial NCT05493709?
The interventions under investigation include: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide (DRUG).
Who is sponsoring clinical trial NCT05493709?
This trial is sponsored by Foresee Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05493709 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.